AbbVie Inc. SG&A Expenses

SG&A Expenses of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including SG&A Expenses growth rates and interactive chart. Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company. It includes administrative


Highlights and Quick Summary

  • SG&A Expenses for the quarter ending June 29, 2020 was $3.53 Billion (a 108.08% increase compared to previous quarter)
  • Year-over-year quarterly SG&A Expenses increased by 112.85%
  • Annual SG&A Expenses for 2019 was $6.94 Billion (a -6.18% decrease from previous year)
  • Annual SG&A Expenses for 2018 was $7.4 Billion (a 17.54% increase from previous year)
  • Annual SG&A Expenses for 2017 was $6.3 Billion (a 7.04% increase from previous year)
  • Twelve month SG&A Expenses ending June 29, 2020 was $8.83 Billion (a 26.92% increase compared to previous quarter)
  • Twelve month trailing SG&A Expenses increased by 27.6% year-over-year
Trailing SG&A Expenses for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$8.83 Billion $6.96 Billion $6.94 Billion $6.92 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical SG&A Expenses of AbbVie Inc.

Most recent SG&A Expensesof ABBV including historical data for past 10 years.

Interactive Chart of SG&A Expenses of AbbVie Inc.

AbbVie Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $3,527.0 $1,695.0
2019 $1,951.0 $1,657.0 $1,654.0 $1,680.0 $6,942.0
2018 $1,929.0 $1,919.0 $1,760.0 $1,791.0 $7,399.0
2017 $1,956.0 $1,457.0 $1,509.0 $1,373.0 $6,295.0
2016 $1,679.0 $1,381.0 $1,466.0 $1,355.0 $5,881.0
2015 $1,737.0 $1,474.0 $1,703.0 $1,473.0 $6,387.0
2014 $3,341.0 $1,595.0 $1,448.0 $1,340.0 $7,724.0
2013 $1,448.0 $1,261.0 $1,406.0 $1,237.0 $5,352.0
2012 $1,411.0 $1,085.0 $1,246.0 $1,247.0 $4,989.0
2011 $4,716.09 $1,177.92 $5,894.0
2010 $3,820.0
2009 $3,348.57

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.